![]() The results: Both groups declined during the 18-month study but overall those given donanemab worsened about 22% more slowly. And because amyloid alone doesn’t cause Alzheimer’s, researchers also tracked levels of another culprit in the brain - abnormal tau. Patients were switched to dummy infusions if enough amyloid cleared out - something that happened to about half within a year. Half received once-a-month infusions of donanemab and half dummy infusions for 18 months. Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Eric Widera of the University of California, San Francisco, wrote in a JAMA editorial accompanying Lilly’s new data. “The modest benefits would likely not be questioned by patients, clinicians or payers if amyloid antibodies were low risk, inexpensive and simple to administer. ![]() Scientists say while these drugs may mark a new era in Alzheimer’s therapy, huge questions remain about which patients should try them and how much benefit they’ll really notice.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |